Not applicableStudy completedNCT01446185What this trial is testingTreatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer PatientsWho this might be right forBreast Cancer Genomic Health®, Inc. 100
Not applicableLooking for participantsNCT06106477What this trial is testingImpact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast CancerWho this might be right forBreast Cancer Medical College of Wisconsin 20
Testing effectiveness (Phase 2)Looking for participantsNCT07616427What this trial is testingFovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast CancerWho this might be right forHR+/HER2+ Early Breast Cancer Second Affiliated Hospital, Zhejiang University, School of Medicine 100
Not applicableLooking for participantsNCT07379918What this trial is testingReal-life Evaluation of Endopredict® in Early HR+/HER2- Breast CancerWho this might be right forBreast Cancer (Early Breast Cancer)Breast Cancer SurvivorsBreast Cancer Prognostic+2 more Assistance Publique - Hôpitaux de Paris 1,000
Not applicableLooking for participantsNCT07084558What this trial is testingABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine ResponsivenessWho this might be right forEarly and Locally Advanced Breast Cancer Austrian Breast & Colorectal Cancer Study Group 350
Testing effectiveness (Phase 2)Active Not RecruitingNCT07130643What this trial is testingEfficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast CancerWho this might be right forHR+/HER2- Breast Cancer Xinhong Wu, PhD 40
Large-scale testing (Phase 3)Ended earlyNCT05128773What this trial is testingStudy of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related ToxicityWho this might be right forBreast Cancer Sanofi 3
Not applicableStudy completedNCT07052734What this trial is testingMiti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer PatientsWho this might be right forBreast Cancer Sun Yat-sen University 2,843
Testing effectiveness (Phase 2)Ended earlyNCT01919229What this trial is testingA Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)Who this might be right forEarly Breast Cancer Novartis Pharmaceuticals 14
Not applicableLooking for participantsNCT05263570What this trial is testingThe Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.Who this might be right forBreast Cancer Shengjing Hospital 200
Post-approval studies (Phase 4)Not Yet RecruitingNCT07630948What this trial is testingAdherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast CancerWho this might be right forBreast CancerAdherence, Medication Institute of Oncology Ljubljana 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06470633What this trial is testingTo Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast CancerWho this might be right forBreast CancerHR+/HER2- Breast Cancer The First Affiliated Hospital with Nanjing Medical University 29
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07317778What this trial is testingChemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast CancerWho this might be right forBreast Cancer Early Stage Breast Cancer (Stage 1-3)HR Positive/HER2 Low Breast Cancer Cancer Institute and Hospital, Chinese Academy of Medical Sciences 249
Very early researchStudy completedNCT02802748What this trial is testingPhase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)Who this might be right forBreast Cancer SOLTI Breast Cancer Research Group 60
Not applicableLooking for participantsNCT07215364What this trial is testingImpact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 InhibitorsWho this might be right forEarly-stage Breast Cancer Spanish Breast Cancer Research Group 74
Testing effectiveness (Phase 2)Looking for participantsNCT07581834What this trial is testingEfficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyWho this might be right forBreast DiseasesBreast NeoplasmsDalpiciclib+3 more Fujian Cancer Hospital 2,000
Post-approval studies (Phase 4)UnknownNCT05809024What this trial is testingSelect the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine TherapyWho this might be right forLocally Advanced Breast CancerHormone Receptor Positive，HER2-negative Breast Cancer Yongsheng Wang 100
Post-approval studies (Phase 4)UnknownNCT05302336What this trial is testingAC vs TC in Patients With HR-positive, HER2-negative Early Breast CancerWho this might be right forBreast CancerChemotherapeutic Toxicity Second Affiliated Hospital, Zhejiang University, School of Medicine 402
Not applicableNot Yet RecruitingNCT07706933What this trial is testingTolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast CancerWho this might be right forBreast Cancer Henan Cancer Hospital 456
Testing effectiveness (Phase 2)Study completedNCT03272477What this trial is testingStudy to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer PatientsWho this might be right forBreast Neoplasms Palleos Healthcare GmbH 257